Xi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xi Wang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Bin Lv
The First Affiliated Hospital of Zhejiang Chinese Medical University
2 shared publications - Qi Huang
Department of Endocrinology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310000, PR China
2 shared publications Chenjuan Wang
The First Clinical Medical School of Zhejiang Chinese Medicine University, Hangzhou, China; Department of Pneumology, The 72nd Group Army Hospital, Huzhou University, Huzhou, China
1 shared publicationDandan Feng
Intensive Care Unit, The First Affiliated hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
1 shared publicationFan Zhang
The First Clinical College of Zhejiang Chinese Medical University, Hangzhou, China
1 shared publicationFengyuan Tian
First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 1 April 2024
- Published by SAGE Publications in Science Progress
- Vol. 107 (2)
Research advancements and perspectives of inflammatory bowel disease: A comprehensive review
Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30–60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action.
- 1 April 2024
- Published by SAGE Publications in Science Progress
- Vol. 107 (2)
Open AccessResearch advancements and perspectives of inflammatory bowel disease: A comprehensive review
Inflammatory bowel disease (IBD) is a chronic inflammatory disease with increasing incidence, such as Crohn's disease and ulcerative colitis. The accurate etiology and pathogenesis of IBD remain unclear, and it is generally believed that it is related to genetic susceptibility, gut microbiota, environmental factors, immunological abnormalities, and potentially other factors. Currently, the mainstream therapeutic drugs are amino salicylic acid agents, corticosteroids, immunomodulators, and biological agents, but the remission rates do not surpass 30–60% of patients in a real-life setting. As a consequence, there are many studies focusing on emerging drugs and bioactive ingredients that have higher efficacy and long-term safety for achieving complete deep healing. This article begins with a review of the latest, systematic, and credible summaries of the pathogenesis of IBD. In addition, we provide a summary of the current treatments and drugs for IBD. Finally, we focus on the therapeutic effects of emerging drugs such as microRNAs and lncRNAs, nanoparticles-mediated drugs and natural products on IBD and their mechanisms of action.
- Open Access
- 2 August 2022
- Published by Springer Nature in European Journal of Nutrition
- Vol. 62 (1) , 139-155
Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines
Purpose: Gut microbiota dysbiosis, a core pathophysiology of irritable bowel syndrome (IBS), is closely related to immunological and metabolic functions. Gut microbiota-based therapeutics have been recently explored in several studies. Bifico is a probiotic cocktail widely used in gastrointestinal disorders which relate to the imbalance of gut microbiota. However, the efficacy and potential mechanisms of Bifico treatment in IBS remains incompletely understood. Methods: Adopting a wrap restraint stress (WRS) -induced IBS mice model. Protective effect of Bifico in IBS mice was examined through abdominal withdrawal reflex (AWR) scores. 16S rDNA, 1H nuclear magnetic resonance (1H-NMR) and western blot assays were performed to analyze alterations of gut microbiota, microbiome metabolites and inflammatory cytokines, respectively. Results: Bifico could decrease intestinal visceral hypersensitivity. Although gut microbiota diversity did not increase, composition of gut microbiota was changed after treatment of Bifico, which were characterized by an increase of Proteobacteria phylum and Actinobacteria phylum, Muribaculum genus, Bifidobacterium genus and a decrease of Parabacteroides genus, Sutterella genus and Lactobacillus genus. Moreover, Bifico elevated the concentration of short-chain fatty acids (SCFAs) and reduced protein levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). From further Spearman’s correlation analysis, Bifidobacterium genus were positively correlated with SCFAs including propionate, butyrate, valerate and negatively correlated with IL-6 and TNF-α. Conclusion: Bifico could alleviate symptoms of IBS mice through regulation of the gut microbiota, elevating production of SCFAs and reducing the colonic inflammatory response.
- 2 August 2022
- Published by Springer Nature in European Journal of Nutrition
- Vol. 62 (1) , 139-155
Open AccessBifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines
Purpose: Gut microbiota dysbiosis, a core pathophysiology of irritable bowel syndrome (IBS), is closely related to immunological and metabolic functions. Gut microbiota-based therapeutics have been recently explored in several studies. Bifico is a probiotic cocktail widely used in gastrointestinal disorders which relate to the imbalance of gut microbiota. However, the efficacy and potential mechanisms of Bifico treatment in IBS remains incompletely understood. Methods: Adopting a wrap restraint stress (WRS) -induced IBS mice model. Protective effect of Bifico in IBS mice was examined through abdominal withdrawal reflex (AWR) scores. 16S rDNA, 1H nuclear magnetic resonance (1H-NMR) and western blot assays were performed to analyze alterations of gut microbiota, microbiome metabolites and inflammatory cytokines, respectively. Results: Bifico could decrease intestinal visceral hypersensitivity. Although gut microbiota diversity did not increase, composition of gut microbiota was changed after treatment of Bifico, which were characterized by an increase of Proteobacteria phylum and Actinobacteria phylum, Muribaculum genus, Bifidobacterium genus and a decrease of Parabacteroides genus, Sutterella genus and Lactobacillus genus. Moreover, Bifico elevated the concentration of short-chain fatty acids (SCFAs) and reduced protein levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). From further Spearman’s correlation analysis, Bifidobacterium genus were positively correlated with SCFAs including propionate, butyrate, valerate and negatively correlated with IL-6 and TNF-α. Conclusion: Bifico could alleviate symptoms of IBS mice through regulation of the gut microbiota, elevating production of SCFAs and reducing the colonic inflammatory response.
- Open Access
- 31 March 2022
- Published by Elsevier in Journal of Ginseng Research
- Vol. 46 (6) , 780-789
Compound K attenuates hyperglycemia by enhancing glucagon-like peptide-1 secretion through activating TGR5 via the remodeling of gut microbiota and bile acid metabolism
- 31 March 2022
- Published by Elsevier in Journal of Ginseng Research
- Vol. 46 (6) , 780-789
Open AccessCompound K attenuates hyperglycemia by enhancing glucagon-like peptide-1 secretion through activating TGR5 via the remodeling of gut microbiota and bile acid metabolism
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 145 (1) , 88-96
The ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI–H716 cells by regulating the RhoA/ROCKs/YAP signaling pathway and cytoskeleton formation
- 1 January 2021
- Published by Elsevier in Journal of Pharmacological Sciences
- Vol. 145 (1) , 88-96
Open AccessThe ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI–H716 cells by regulating the RhoA/ROCKs/YAP signaling pathway and cytoskeleton formation